ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Clinical Operations at Cogent Biosciences - ApplyBlast

Associate Director, Clinical Operations

Cogent Biosciences

3 months ago

3.8 on Glassdoor

Boulder, Colorado, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Associate Director, Clinical Operations will lead global clinical studies, overseeing timelines, budgets, and quality while providing strategic oversight of CROs and vendors. This role balances hands‑on study management with broader operational strategy, risk identification, and cross‑functional collaboration to drive execution excellence across early‑stage development programs.

Responsibilities

Lead global clinical studies ensuring timeline, budget, and quality delivery
Develop and monitor study performance metrics and risk mitigation strategies
Oversee CRO and vendor relationships, contracts, and site monitoring activities

Skills

Qualifications

BS/BA Degree in science or health-related field

About Cogent Biosciences

cogentbio.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2014

View Profile

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, including cancers, autoimmune conditions, and rare diseases. The company leverages validated biology to design best-in-class small molecule therapeutics, with its lead program bezuclastinib targeting conditions such as Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). Cogent operates discovery and development offices in Boulder, Colorado and Waltham, Massachusetts, and is actively advancing clinical-stage programs including a Phase 3 trial and an FDA-accepted NDA for bezuclastinib.